ReviewNature reviews. Nephrology2013
Chronotherapy improves blood pressure control and reduces vascular risk in CKD.
Review in Nature reviews. Nephrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 61 citations in OpenAlex.
- Nondipping blood pressure pattern predicts cardiovascular events and mortality in patients with atherosclerotic peripheral vascular disease.Vascular medicine (London, England) · 2023Trial
- Trial
- Review
- Three-Year Longitudinal Evaluation of Timing Effects on Subcutaneous Immunotherapy Efficacy and Safety in Allergic Rhinitis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Article
- Morning vs. evening: the role of exercise timing in enhancing fat oxidation in young men.Frontiers in physiology · 2025Article
- Diabetic Neuropathic Pain and Circadian Rhythm: A Future Direction Worthy of Study.Journal of pain research · 2024Review
- A wrinkle in time: circadian biology in pulmonary vascular health and disease.American journal of physiology. Lung cellular and molecular physiology · 2022Article
- Circadian Rhythms, Disease and Chronotherapy.Journal of biological rhythms · 2021Review
- Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension.Nanomedicine : nanotechnology, biology, and medicine · 2021Article
- Circadian rhythm as a therapeutic target.Nature reviews. Drug discovery · 2021Review
- Assessment of Selected Clock Proteins (CLOCK and CRY1) and Their Relationship with Biochemical, Anthropometric, and Lifestyle Parameters in Hypertensive Patients.Biomolecules · 2021Article
- Silicon Nanofluidic Membrane for Electrostatic Control of Drugs and Analytes Elution.Pharmaceutics · 2020Article
- Utilization of antihypertensive drugs among chronic kidney disease patients: Results from the Chinese cohort study of chronic kidney disease (C-STRIDE).Journal of clinical hypertension (Greenwich, Conn.) · 2020Article
- Possible interesting link between dipping status and morning surge for subclinical target organ damage in hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2019Article
- Emerging relevance of circadian rhythms in headaches and neuropathic pain.Acta physiologica (Oxford, England) · 2019Review
- Sleep-Time Ambulatory BP Is an Independent Prognostic Marker of CKD.Journal of the American Society of Nephrology : JASN · 2017Article
- One-size-fits-all management of hypertension: a key to poor control of hypertension in low income settings in sub-Saharan Africa?Annals of translational medicine · 2016Article
- The deadly line linking sympathetic overdrive, dipping status and vascular risk: critical appraisal and therapeutic implications.Hypertension research : official journal of the Japanese Society of Hypertension · 2016Article
- Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks.Hypertension research : official journal of the Japanese Society of Hypertension · 2016Review
- The Circadian Clock in the Regulation of Renal Rhythms.Journal of biological rhythms · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with chronic kidney disease (CKD), the prevalence of increased blood pressure during sleep and blunted sleep-time-relative blood pressure decline (a nondipper pattern) is very high and increases substantially with disease severity. Elevated blood pressure during sleep is the major criterion for the diagnoses of hypertension and inadequate therapeutic ambulatory blood pressure control in these patients. Substantial, clinically meaningful ingestion-time-dependent differences in the safety, efficacy, duration of action and/or effects on the 24 h blood pressure pattern of six different classes of hypertension medications and their combinations have been substantiated. For example, bedtime ingestion of angiotensin-converting-enzyme inhibitors and angiotensin-receptor blockers is more effective than morning ingestion in reducing blood pressure during sleep and converting the 24 h blood pressure profile into a dipper pattern. We have identified a progressive reduction in blood pressure during sleep--a novel therapeutic target best achieved by ingestion of one or more hypertension medications at bedtime--as the most significant predictor of decreased cardiovascular risk in patients with and without CKD. Recent findings suggest that in patients with CKD, ambulatory blood pressure monitoring should be used for the diagnosis of hypertension and assessment of cardiovascular disease risk, and that therapeutic strategies given at bedtime rather than on awakening are preferable for the management of hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.